PDF(Pubmed)
Abstract：
OBJECTIVE: Most patients with colorectal cancer (CRC) show no early symptoms, and tumor markers have low sensitivity and specificity. We therefore investigated the ability of serum fibrin degradation complex DR-70 plus traditional tumor markers to diagnose CRC.
METHODS: We retrospectively screened patients with CRC or non-malignant colorectal diseases, as well as healthy individuals, for inclusion in this study. The individuals\' clinical characteristics were recorded, and serum samples were collected. Expression levels of DR-70 and conventional tumor markers were measured by enzyme-linked immunosorbent assay and electrochemiluminescence.
RESULTS: DR-70 levels differed significantly among patients with CRC, patients with benign colorectal diseases, and healthy individuals. Receiver operating characteristic curve analysis identified DR-70 as a conventional tumor marker with the highest sensitivity and the second-highest specificity after carcinoembryonic antigen.
CONCLUSIONS: This study identified DR-70 as a reliable marker for the detection, differentiation, and progression of CRC, with good sensitivity and specificity. DR-70 measurement could greatly improve the efficacy of CRC diagnosis when used together with other tumor markers.
METHODS: We retrospectively screened patients with CRC or non-malignant colorectal diseases, as well as healthy individuals, for inclusion in this study. The individuals\' clinical characteristics were recorded, and serum samples were collected. Expression levels of DR-70 and conventional tumor markers were measured by enzyme-linked immunosorbent assay and electrochemiluminescence.
RESULTS: DR-70 levels differed significantly among patients with CRC, patients with benign colorectal diseases, and healthy individuals. Receiver operating characteristic curve analysis identified DR-70 as a conventional tumor marker with the highest sensitivity and the second-highest specificity after carcinoembryonic antigen.
CONCLUSIONS: This study identified DR-70 as a reliable marker for the detection, differentiation, and progression of CRC, with good sensitivity and specificity. DR-70 measurement could greatly improve the efficacy of CRC diagnosis when used together with other tumor markers.
摘要：
目的：大多数结直肠癌（CRC）患者没有早期症状，肿瘤标志物的敏感性和特异性较低。因此，我们研究了血清纤维蛋白降解复合物DR-70加上传统肿瘤标志物诊断CRC的能力。
方法：我们回顾性筛查了CRC或非恶性结直肠疾病患者，以及健康的个体，纳入本研究。记录个体的临床特征，并收集血清样本。通过酶联免疫吸附法和电化学发光法检测DR-70和常规肿瘤标志物的表达水平。
结果：DR-70水平在CRC患者中存在显著差异，良性结直肠疾病患者，和健康的个体。受试者工作特征曲线分析将DR-70确定为常规肿瘤标志物，其灵敏度最高，特异性仅次于癌胚抗原。
结论：这项研究确定DR-70是检测的可靠标记，分化,和CRC的进展，具有良好的敏感性和特异性。当与其他肿瘤标志物一起使用时，DR-70测量可以大大提高CRC诊断的效率。
方法：我们回顾性筛查了CRC或非恶性结直肠疾病患者，以及健康的个体，纳入本研究。记录个体的临床特征，并收集血清样本。通过酶联免疫吸附法和电化学发光法检测DR-70和常规肿瘤标志物的表达水平。
结果：DR-70水平在CRC患者中存在显著差异，良性结直肠疾病患者，和健康的个体。受试者工作特征曲线分析将DR-70确定为常规肿瘤标志物，其灵敏度最高，特异性仅次于癌胚抗原。
结论：这项研究确定DR-70是检测的可靠标记，分化,和CRC的进展，具有良好的敏感性和特异性。当与其他肿瘤标志物一起使用时，DR-70测量可以大大提高CRC诊断的效率。
